News
BIIB
210.65
+0.85%
1.78
Biogen Raised to Outperform From Peer Perform by Wolfe Research
Dow Jones · 9h ago
Biogen Price Target Announced at $300.00/Share by Wolfe Research
Dow Jones · 9h ago
Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target
Benzinga · 9h ago
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE) and Biogen (BIIB)
TipRanks · 11h ago
Barclays Keeps Their Hold Rating on Biogen (BIIB)
TipRanks · 18h ago
Regeneron, Tenet leads top healthcare companies with highest earnings beats
Seeking Alpha · 1d ago
Biogen’s Long-Term Spinraza Study Wraps Up, Setting the Stage for Key SMA Data
TipRanks · 2d ago
Weekly Report: what happened at BIIB last week (0803-0807)?
Weekly Report · 3d ago
Should Biogen’s Profit Squeeze Amid Rising New-Therapy Sales Prompt Action From Biogen (BIIB) Investors?
Simply Wall St · 4d ago
Insiders Shake Up General Dynamics, Thermo Fisher, Carvana, Biogen, Charles Schwab
TipRanks · 5d ago
Biogen (BIIB) Q2 2026 Earnings Call Transcript
The Motley Fool · 6d ago
Is Biogen (BIIB) Fully Priced After Earnings Raised Revenue But Cut Profit?
Simply Wall St · 6d ago
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
NASDAQ · 6d ago
Press Release: Biogen Completes Acquisition of RayThera Inc.
Dow Jones · 08/06 22:15
Biogen Extends Felzartamab Kidney Rejection Trial, Bolstering Long-Term Pipeline Story
TipRanks · 08/06 16:41
Biogen Insider Move: High-Profile Director Cashes Out in Six-Figure Stock Sale
TipRanks · 08/06 02:07
Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement
Seeking Alpha · 08/05 17:50
Mizuho Maintains Outperform on Biogen, Raises Price Target to $241
Benzinga · 08/04 18:11
Biogen price target raised to $241 from $221 at Mizuho
TipRanks · 08/04 12:17
Biogen Price Target Raised to $215.00/Share From $200.00 by Citigroup
Dow Jones · 08/03 18:47
More
Webull provides a variety of real-time BIIB stock news. You can receive the latest news about Biogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About BIIB
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.